RxSight (RXST)
(Delayed Data from NSDQ)
$56.45 USD
+2.12 (3.90%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $56.47 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Cash flow Statements
Fiscal Year End for RxSight, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -48.61 | -66.76 | -48.69 | 27.58 | NA |
Depreciation/Amortization & Depletion | -1.59 | 3.17 | 4.45 | 3.65 | NA |
Net Change from Assets/Liabilities | -9.07 | -7.41 | -2.68 | -7.85 | NA |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Operating Activities | 17.68 | 12.15 | 2.21 | -58.58 | NA |
Net Cash From Operating Activities | -41.59 | -58.85 | -44.71 | -35.20 | NA |
Property & Equipment | -4.81 | -2.39 | -1.94 | -2.54 | NA |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Investments | -17.32 | 42.34 | -79.97 | 18.13 | NA |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Net Cash from Investing Activities | -22.13 | 39.95 | -81.91 | 15.59 | NA |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 105.96 | 7.83 | 121.93 | 1.02 | NA |
Issuance (Repayment) of Debt | -41.58 | -0.76 | 14.97 | 24.86 | NA |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Financing Activities | -2.86 | -0.73 | 0.44 | -0.64 | NA |
Net Cash from Financing Activities | 61.52 | 6.33 | 137.34 | 25.24 | NA |
Effect of Exchange Rate Changes | 0.01 | -0.01 | -0.01 | 0.00 | NA |
Net Change In Cash & Equivalents | -2.19 | -12.58 | 10.72 | 5.63 | NA |
Cash at Beginning of Period | 12.60 | 25.17 | 14.46 | 8.83 | NA |
Cash at End of Period | 10.40 | 12.60 | 25.17 | 14.46 | NA |
Diluted Net EPS | -1.41 | -2.41 | -3.57 | NA | NA |
Fiscal Year End for RxSight, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -15.18 | -9.10 | -48.61 | -39.43 | -27.02 |
Depreciation/Amortization & Depletion | -1.62 | -0.37 | -1.59 | -1.10 | -0.64 |
Net Change from Assets/Liabilities | -7.51 | -4.65 | -9.07 | -5.87 | -5.28 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 10.97 | 4.81 | 17.68 | 13.10 | 7.63 |
Net Cash From Operating Activities | -13.34 | -9.31 | -41.59 | -33.29 | -25.31 |
Property & Equipment | -3.49 | -1.97 | -4.81 | -3.22 | -2.57 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -87.88 | 26.24 | -17.32 | -23.47 | -41.40 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -91.37 | 24.27 | -22.13 | -26.70 | -43.97 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 122.09 | 10.15 | 105.96 | 102.37 | 88.44 |
Issuance (Repayment) of Debt | -2.17 | -2.16 | -41.58 | -41.54 | -20.42 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.46 | 0.00 | -2.86 | -2.87 | -1.83 |
Net Cash from Financing Activities | 119.47 | 7.99 | 61.52 | 57.96 | 66.20 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 14.75 | 22.95 | -2.19 | -2.03 | -3.08 |
Cash at Beginning of Period | 10.40 | 10.40 | 12.60 | 12.60 | 12.60 |
Cash at End of Period | 25.16 | 33.36 | 10.40 | 10.57 | 9.51 |
Diluted Net EPS | -0.16 | -0.25 | -0.24 | -0.35 | -0.40 |